142 related articles for article (PubMed ID: 31657688)
1.
Shah A; Seth AK
Curr Drug Discov Technol; 2021; 18(1):75-82. PubMed ID: 31657688
[TBL] [Abstract][Full Text] [Related]
2. In Silico Discovery of Novel Flavonoids as Poly ADP Ribose Polymerase (PARP) Inhibitors.
Shah A; Parmar G; Seth AK
Curr Comput Aided Drug Des; 2021; 17(3):344-350. PubMed ID: 32268868
[TBL] [Abstract][Full Text] [Related]
3. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
4.
Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
6.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
7. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
8. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
[TBL] [Abstract][Full Text] [Related]
10. An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
Majhi M; Ali MA; Limaye A; Sinha K; Bairagi P; Chouksey M; Shukla R; Kanwar N; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(27):2355-2366. PubMed ID: 30499396
[TBL] [Abstract][Full Text] [Related]
11. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
Liang Y; Zhang T; Zhang J
Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
[TBL] [Abstract][Full Text] [Related]
12. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
[TBL] [Abstract][Full Text] [Related]
13. Ligand and structure based hierarchical virtual screening cascade for finding novel epidermal growth factor receptor inhibitors.
Huo D; Sun Z; Wang M; Yan A
Chem Biol Drug Des; 2024 Jan; 103(1):e14375. PubMed ID: 37849030
[TBL] [Abstract][Full Text] [Related]
14. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
Jarapula R; Badavath VN; Rekulapally S; Manda S
Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
[TBL] [Abstract][Full Text] [Related]
15. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
[TBL] [Abstract][Full Text] [Related]
16. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
17. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
18. Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro.
Singh P; Bast F
Invest New Drugs; 2015 Jun; 33(3):575-93. PubMed ID: 25895100
[TBL] [Abstract][Full Text] [Related]
19. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
[TBL] [Abstract][Full Text] [Related]
20. In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
Xiang M; Lei K; Fan W; Lin Y; He G; Yang M; Chen L; Mo Y
Drug Des Devel Ther; 2013; 7():789-839. PubMed ID: 23990708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
